CELYAD S.A.

/CELYAD S.A.

We are a clinical-stage biopharmaceutical company focused on the development of chimeric antigen receptor (CAR) T-lymphocytes (T-cells), or CAR-T, cell-based therapies for the treatment of cancer.

Symbol

Last Closing Price
$13.29

Shares
2,000,000

Anticipated Date
September 12, 2019

Underwriters

This offering is no longer available

To view the prospectus for , or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange